Background: Vitiligo is a common chronic disease associated with physical effects, psychological impacts, and impaired quality of life (QoL). Lesions in acral areas are resistant to treatments. Since these areas are exposed and visible, they have a profound effect on patients' self-confidence. Despite the high prevalence of these conditions, information in this field, especially for Iranian patients, is scarce.
Objectives: To study the clinical profile of patients with vitiligo lesions in the acral areas, assess the burden of QoL impairment, and investigate the association between patient's characteristics and their QoL outcomes
Methods: A total of 84 patients with non-segmental vitiligo who had involvement in resistant treatment areas were recruited in this study. Clinical characteristics and disease outcomes, with a special emphasis on the quality of life (QoL), were investigated using the Dermatology Life Quality Index (DLQI) questionnaire. Furthermore, the extent of the disease was calculated by utilizing the Vitiligo Area Scoring Index (VASI). Descriptive and comparative analyses were conducted using SPSS software (version 29).
Results: The most common comorbidity observed among the patients was various types of immune diseases. The mean total score of DLQI was 8.1, indicating a moderate effect of the disease on the patient's life since the score falls within the range of 6-10. The Kruskal-Wallis non-parametric test illustrated a significant difference in QoL among different age groups (P=0.020). The results indicated a positive, direct, and significant relationship between the extent of the disease and DLQI (r=0.269,;P=0.013). Nonetheless, the relationship between the engagement of the genital area in married patients and difficulties in sexual relations was not found to be statistically significant at α=0.05.
Conclusion: The involvement of end-extremities based on existing studies is a frequent occurrence in vitiligo. These affected areas hold considerable significance in terms of the patient's quality of life (QoL) due to their prominent visibility and resistance to available treatments. Considering the high prevalence of psychological consequences, diversity in skin phototypes, and social acceptance, regional studies are necessary for more efficient and responsive medical management integrated with psychosocial assistance.
Bergqvist C, Ezzedine K. Vitiligo: A Review. Dermatology.2020;236(6):571-92. doi: 10.1159/000506103. [PubMed: 32155629].
Speeckaert R, van Geel N. Distribution patterns in generalized vitiligo. J Eur Acad Dermatol Venereol. 2014;28(6):755-62. doi: 10.1111/jdv.12171. [PubMed: 23651011].
Silpa-Archa N, Pruksaeakanan C, Angkoolpakdeekul N, Chaiyabutr C, Kulthanan K, Ratta-Apha W, et al. Relationship between depression and quality of life among vitiligo patients: a self-assessment questionnaire-based study. Clin Cosmet Investig Dermatol. 2020;13:511-20. doi: 10.2147/CCID.S265349. [PubMed: 32801827].
Ezzedine K, Grimes PE, Meurant JM, Seneschal J, Léauté‐Labrèze C, Ballanger F, et al. Living with vitiligo: results from a national survey indicate differences between skin phototypes. Br J Dermatol. 2015;173(2):607-9. doi: 10.1111/bjd.13839. [PubMed: 25892476].
Massarrat M-S, Tahaghoghi-Mehrizi S. Iranian national health survey: a brief report. Arch Iranian Med. 2002;5(2):73-9.
6. Hamidizadeh N, Ranjbar S, Ghanizadeh A, Parvizi MM, Jafari P, Handjani F. Evaluating prevalence of depression, anxiety and hopelessness in patients with Vitiligo on an Iranian population. Health Qual Life Outcomes. 2020;18(1):20. doi: 10.1186/s12955-020-1278-7. [PubMed: 32013982].
7. Ucuz I, Altunisik N, Sener S, Turkmen D, Kavuran N, Marsak M, et al. Quality of life, emotion dysregulation, attention deficit and psychiatric comorbidity in children and adolescents with vitiligo. Clin Exp Dermatol. 2021;46(3):510-5. doi: 10.1111/ced.14196. [PubMed: 32064670].
Bastonini E, Bellei B, Filoni A, Kovacs D, Iacovelli P, Picardo M. Involvement of non-melanocytic skin cells in vitiligo. Exp Dermatol. 2019;28(6):667-73. doi: 10.1111/exd.13868. [PubMed: 30582762].
Ongenae K, Beelaert L, van Geel N, Naeyaert JM. Psychosocial effects of vitiligo. J Eur Acad Dermatol Venereol. 2006;20(1):1-8. doi: 10.1111/j.1468-3083.2005.01369.x. [PubMed: 16405601].
Bin Saif GA, Al-Balbeesi AO, Binshabaib R, Alsaad D, Kwatra SG, Alzolibani AA, et al. Quality of life in family members of vitiligo patients: a questionnaire study in Saudi Arabia. Am J Clin Dermatol. 2013;14(6):489-95. doi: 10.1007/s40257-013-0037-5. [PubMed: 23839260].
Finlay AY, Khan G. Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use. Clin Exp Dermatol. 1994;19(3):210-6. doi: 10.1111/j.1365-2230.1994.tb01167.x. [PubMed: 8033378].
Aghaei S, Sodaifi M, Jafari P, Mazharinia N, Finlay AY. DLQI scores in vitiligo: reliability and validity of the Persian version. BMC Dermatol. 2004;4(1):1-5. doi: 10.1186/1471-5945-4-8. [PubMed: 15294022].
Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo Area Scoring Index. Arch Dermatol. 2004;140(6):677-83. doi: 10.1001/archderm.140.6.677. [PubMed: 15210457].
Bae JM, Zubair R, Ju HJ, Kohli I, Lee HN, Eun SH, et al. Development and validation of the fingertip unit for assessing Facial Vitiligo Area Scoring Index. J Am Acad Dermatol. 2022;86(2):387-93. doi: 10.1016/j.jaad.2021.06.880.
van Geel N, Lommerts J, Bekkenk M, Wolkerstorfer A, Prinsen CAC, Eleftheriadou V, et al. Development and validation of the vitiligo extent score (VES): an international collaborative initiative. J Invest Dermatol. 2016;136(5):978-84. doi: 10.1016/j.jid.2015.12.040. [PubMed: 26827762].
Chaweekulrat P, Silpa-Archa N, Apinuntham C, Chaiyabutr C, Wongpraparut C. Reliability, validity and feasibility of the vitiligo extent score (VES) and self-assessment vitiligo extent score (SA-VES) among vitiligo patients: a cross-cultural validation. Clin Cosmet Investig Dermatol. 2021;14:949-57. doi: 10.2147/CCID.S324073. [PubMed: 34349539].
Amer AA, Gao XH. Quality of life in patients with vitiligo: an analysis of the dermatology life quality index outcome over the past two decades. Int J Dermatol. 2016;55(6):608-14. doi: 10.1111/ijd.13198. [PubMed: 26749040].
Silpa-Archa N, Pruksaeakanan C, Angkoolpakdeekul N, Chaiyabutr C, Kulthanan K, Ratta-Apha W, et al. Relationship between depression and quality of life among vitiligo patients: a self-assessment questionnaire-based study. Clinical, cosmetic and investigational dermatology. 2020;13:511. DOI: 10.2147/CCID.S265349. [PubMed: 32801827].
Dolatshahi M, Ghazi P, Feizy V, Hemami MR. Life quality assessment among patients with vitiligo: comparison of married and single patients in Iran. Indian J Dermatol Venereol Leprol. 2008;74(6):700. doi: 10.4103/0378-6323.45141. [PubMed: 19177700].
Kostopoulou P, Jouary T, Quintard B, Ezzedine K, Marques S, Boutchnei S, et al. Objective vs. subjective factors in the psychological impact of vitiligo: the experience from a French referral centre. Br J Dermatol. 2009;161(1):128-33. doi: 10.1111/j.1365-2133.2009.09077.x. [PubMed: 19298280].
Ongenae K, Van Geel N, De Schepper S, Naeyaert JM. Effect of vitiligo on self‐reported health‐related quality of life. Br J Dermatol. 2005;152(6):1165-72. doi: 10.1111/j.1365-2133.2005.06456.x. [PubMed: 15948977].
Karelson M, Silm H, Kingo K. Quality of life and emotional state in vitiligo in an Estonian sample: comparison with psoriasis and healthy controls. Acta Derm Venereol. 2013;93(4):446-50. doi: 10.2340/00015555-1520. [PubMed: 23306792].
Al Robaee AA. Assessment of quality of life in Saudi patients with vitiligo in a medical school in Qassim province, Saudi Arabia. Saudi Med J. 2007;28(9):1414-7. [PubMed: 17768471].
Sangma LN, Nath J, Bhagabati D. Quality of life and psychological morbidity in vitiligo patients: a study in a teaching hospital from north-East India. Indian J Dermatol. 2015;60(2):142-6. doi: 10.4103/0019-5154.152508. [PubMed: 25814701].
Hammam MA, Yasien HA, Algharably AF. Effect of vitiligo area scoring index on the quality of life in patients with vitiligo. Menoufia Med J. 2019;32(1):244-9. doi: 10.4103/mmj.mmj_399_17.
Borimnejad L, Yekta ZP, Nikbakht-Nasrabadi A, Firooz A. Quality of life with vitiligo: comparison of male and female muslim patients in Iran. Gend Med. 2006;3(2):124-30. doi: 10.1016/s1550-8579(06)80201-9. [PubMed: 16860271].